Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 67Neoplasm Metastasis 6Prostatic Neoplasms, Castration-Resistant 4Metastatic Castration-resistant Prostate Cancer 4Neoplasms 3Prostate Cancer Metastatic 2Metastatic Castration Resistant Prostate Cancer 2Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Newly Diagnosed Oligometastatic Prostate Cancer 1Metastatic Castration-sensitive Prostate Cancer 1Hyperaldosteronism 1Castration-resistant Prostate Cancer 1Castrate-resistant Prostate Cancer 1Adenocarcinoma 1

Interventions

Prednisone 1Dexamethasone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hyperaldosteronism × Abiraterone Acetate × Clear all
NCT01867710 2019-07-05

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Janssen Pharmaceutica N.V., Belgium

Phase 2 Completed
164 enrolled 22 charts
Genitourinary

Hyperaldosteronism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡